MetaCap

Standard BioTools (LAB) vs Pacific Biosciences of California (PACB)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Pacific Biosciences of California (PACB) has outperformed Standard BioTools (LAB) over the past year, losing 26.6% versus a loss of 54.3%. Over five years, LAB leads with a -86.5% price change compared with -93.0% for PACB. Pacific Biosciences of California is the larger company by market cap ($508.9 million vs $249.1 million), about 2.0 times the size.

Standard BioTools converts more of its revenue into profit, with a net margin of -87.8% versus -341.5%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

LAB-54.28%PACB-26.58%
+35%-15%-65%
Nov 21, 20251 yearNov 20, 2026
LAB-85.95%PACB-93.84%
+10%-46%-102%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

LAB versus PACB key metrics
MetricLABPACB
Share price$0.631$1.63
Market cap$249.11M$508.95M
1-day change+2.82%-7.39%
YTD return-50.70%-12.83%
1-year return-54.28%-26.58%
5-year return-86.55%-93.01%
EPS (TTM)$-0.09$-0.42
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$85.33M$160.00M
Revenue growth (YoY)-6.24%+3.89%
Net income (latest FY)$-74.90M$-546.38M
Gross margin49.86%28.61%
Operating margin-129.20%-346.15%
Net margin-87.77%-341.47%
52-week high$1.72$3.44
52-week low$0.39$1.07
Distance from 52-week high-63.31%-52.62%
Analyst consensusnonebuy
Avg. price target upside+113.95%+68.10%
Average volume1.16M13.23M
Shares outstanding394.79M312.24M
Employees385485
SectorIndustrialsIndustrials
IndustryBiotechnology: Laboratory Analytical InstrumentsBiotechnology: Laboratory Analytical Instruments

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • Pacific Biosciences of California is about 2.0 times larger than Standard BioTools by market value ($508.95M vs $249.11M).
  • PACB has outperformed LAB by 27.7 percentage points over the past year.
  • Standard BioTools is more profitable, keeping -87.8 cents of every revenue dollar as net income versus -341.5 cents for Pacific Biosciences of California.
  • Pacific Biosciences of California grew revenue faster in its latest fiscal year (+3.89% vs -6.24%).

About Standard BioTools

LAB stock →

Standard BioTools Inc., together with its subsidiaries, develops, manufactures, and sells a range of instrumentation, consumables, and services to scientists and biomedical researchers to develop therapeutics in the Americas, Europe, the Middle East, Africa, and the Asia pacific. The company operates through Proteomics and Genomics segments.

Industrials · Biotechnology: Laboratory Analytical Instruments · 385 employees

About Pacific Biosciences of California

PACB stock →

Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing solutions to resolve genetically complex problems.

Industrials · Biotechnology: Laboratory Analytical Instruments · 485 employees

LAB vs PACB FAQ

Which is bigger, Standard BioTools or Pacific Biosciences of California?

Pacific Biosciences of California (PACB) is larger, with a market capitalization of $508.95M compared with $249.11M for Standard BioTools (LAB).

Which stock has performed better over the past year, LAB or PACB?

PACB returned -26.58% over the past 12 months, compared with -54.28% for LAB (price return, excluding dividends). Past performance does not predict future results.

Are Standard BioTools and Pacific Biosciences of California in the same industry?

Yes. Both are classified in the Biotechnology: Laboratory Analytical Instruments industry within the Industrials sector.

More comparisons